X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/breakthrough-in-lung-cancer-treatment-dizal-to-unveil-groundbreaking-results-of-sunvozertinib-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-at-2024-asco-annual-meeting-302125904.html
https://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-to-sunvozertinib-for-the-first-line-treatment-of--patients-with-advanced-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-302109862.html
https://www.prnewswire.com/news-releases/dizals-sunvozertinib-pivotal-study-results-published-in-the-lancet-respiratory-medicine-302013864.html
https://www.prnewswire.com/news-releases/dizal-impresses-with-its-differentiated-hematological-oncology-portfolio-at-2023-ash-302012271.html
https://endpts.com/dizal-presents-updated-phii-ptlc-data-plans-to-file-for-accelerated-approval-in-the-us-next-year/
https://www.fiercebiotech.com/biotech/high-tumor-response-astrazeneca-spinout-dizal-explores-fda-path-and-us-partner-ptcl-drug
https://www.prnewswire.com/news-releases/dizals-golidocitinib-pivotal-trial-demonstrates-superior-and-durable-clinical-benefits-for-patients-with-rr-ptcl-in-oral-presentation-at-2023-ash-302010729.html
https://www.prnewswire.com/news-releases/sunvozertinib-demonstrates-best-in-class-potential-as-a-first-line-treatment-for-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer-patients-301964303.html
https://www.prnewswire.com/news-releases/golidocitinib-granted-priority-review-by-china-nmpa-for-the-treatment-of-rr-ptcl-301934854.html
Market Place
Share 
